[1]Ziqneqo AL, Piluso A, Giannini C.HBV and HCV chronic in-fection Autoimmune manifestations and lymphoproliferation[J].Autoimmunity Reviews, 2008, 8 (2) :107-111.
|
[2]Kamath BM, Piccoli DA.Heritable disorders of the bileducts[J].Gastroenterol Clin Noth Am, 2003, 32 (3) :857-875.
|
[3]赵新颜, 王宝恩, 贾继东.36例先天性肝纤维的临床病理特点[J].中华消化杂志, 2005, 25 (12) :191-193.
|
[4]赵新颜, 王泰龄, 贾继东.先天性肝纤维14例临床病理特点[J].临床肝胆病杂志, 2010, 26 (2) :191-193.
|
[5]Adeva M, El-Youssef M, Rossettis, et al.Clinical and mo-lecular characterization defines a broadened spectrum of au-tosomal recessive polycystic kidney disease (ARPKD) [J].Medicine (Baltimore) , 2006, 85 (1) :1-21.
|
[6]Akhan O, Karaosmano-lu AD, Ergen B.Imaging findings incongenital hepatic fibrosis[J].Eur J Radiol, 2007, 61 (1) :18-24.
|
[7]彭向欣, 王泰龄.肝脏疾病临床病理学[M].北京:化学工业出版社, 2010:134-135, 237.
|
[8]Shorbagi A, Bayraktar Y.Exerience of a single center withcongenital hepatic fibrosis:a review of the literature[J].World J Gastroenterol, 2010, 16 (6) :683-690.
|
[1] | Ren Yan, Zheng SuJun. Experience in clinical treatment of drug-induced liver injury:a case report[J]. Journal of Clinical Hepatology, 2017, 33(12): 2395-2396. doi: 10.3969/j.issn.1001-5256.2017.12.029 |
[2] | Liu ChengHai, Zhu ChunWu. Epidemic features, major causes, and diagnostic evaluation of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(5): 829-832. doi: 10.3969/j.issn.1001-5256.2017.05.007 |
[3] | Wang YueZhi, Zhang Yu. Research advances in drug- induced liver injury in the elderly[J]. Journal of Clinical Hepatology, 2016, 32(4): 821-824. doi: 10.3969/j.issn.1001-5256.2016.04.049 |
[4] | Yang Jun, Yu YaLi, Zheng ZhangQing. Clinical features of drug- induced liver injury and primary biliary cirrhosis: a comparative analysis[J]. Journal of Clinical Hepatology, 2016, 32(4): 728-731. doi: 10.3969/j.issn.1001-5256.2016.04.024 |
[5] | Shen ShuiYing, Wu Jun. Acute liver failure caused by antitubercular drugs: a report of one case[J]. Journal of Clinical Hepatology, 2015, 31(9): 1483-1484. doi: 10.3969/j.issn.1001-5256.2015.09.029 |
[6] | Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2015, 31(11): 1752-1769. doi: 10.3969/j.issn.1001-5256.2015.11.002 |
[7] | Tu YanYun, Chen HaiYan, Liu XuDong. Research progress in antiviral therapy for decompensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 460-464. doi: 10.3969/j.issn.1001-5256.2015.03.036 |
[8] | Qi YaBin, Qiu Ling, Jiang HongLi, Zhang Rui, Hu YuLin. Clinical characteristics of drug-induced liver injury: an analysis of 394 cases[J]. Journal of Clinical Hepatology, 2014, 30(5): 438-441. doi: 10.3969/j.issn.1001-5256.2014.05.014 |
[9] | Yu Zheng, Jia JiDong. Risk factors, diagnostic criteria, and drug discontinuation criteria for drug- induced liver injury[J]. Journal of Clinical Hepatology, 2013, 29(9): 674-677. doi: 10.3969/j.issn.1001-5256.2013.09.010 |
[10] | Xu XiuHua, Xiang XiaoXing, Long AiHua, Liu Dan, Wang JingSong. Differential distribution of age and HBV serological markers in liver cirrhosis and non-cirrhotic patients with primary liver cancer[J]. Journal of Clinical Hepatology, 2013, 29(3): 214-216. |
[11] | Peng JianPing, Sun KeWei, Wu YuNan. Impact of early virological response to antiviral treatment on the outcomes of hepatitis B-associated liver failure [J]. Journal of Clinical Hepatology, 2012, 28(10): 752-755. |
[12] | Hu XiaoLi, Zhao HongWei, Wu XiaoYan, Niu JunQi. Prevalence of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2012, 28(6): 413-416+421. |
[13] | Hu XingWu, Qi ChangJin, Zhou HongXing. Therapeutic efficacy of ursodeoxycholic acid for drug-induced liver disease[J]. Journal of Clinical Hepatology, 2012, 28(9): 695-696. |
[14] | Yu XiaoFang. Captopril-induced liver injury and considerations for hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(7): 549-550. |
[15] | Su HaiBin, Wang HuiFen. Clinical significance of drug-induced liver failure[J]. Journal of Clinical Hepatology, 2012, 28(10): 738-739+747. |
[16] | Niu ChunYan, Gao BaoHua, Zheng JianYun, Wu FangXiong, Wang Wen, Luo JianMei, Zheng NaiQing. The correlations between HBV quantity in the liver tissue and the severity of liver tissue injury in chronic hepatitis B and hepatic cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 277-279. |
[17] | Gao Zhen, Zhang LunLi. Toll like receptors mediated innate immune responses against HBV infection[J]. Journal of Clinical Hepatology, 2011, 27(6): 667-669+673. |
[18] | Yuan JianGuo, Wang XinGuo, Cui Xia, Liu FengHua, Wang FengHua, Song JiKui, Zhao HongKui. The activation of rat hepatic stellate cells stimulated with hepatitis B virus in vitro[J]. Journal of Clinical Hepatology, 2011, 27(2): 163-165. |
[19] | Zhu ChaoHui, Li Nan, Wu Kai, Wang XueMing, Zhang Lin, Zhai JunShan, Wang YanMei. The effect of S-adenosyl-methionine treatment on drug-induced liver injury[J]. Journal of Clinical Hepatology, 2010, 26(6): 651-653. |
[20] | Wang Xia, Chen ChangYun, Zhang JiaJun, Shi Jun, Zhu XinYu, Wang Yan, Wu JianRui. Detection and clinical characteristics analysis of occult hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2007, 23(4): 243-245. |